Evidence map›Paper›PMID 35480692›Full record

ArticleRSC advances2021

Architecture of a multi-channel and easy-to-make microfluidic paper-based colorimetric device (μPCD) towards selective and sensitive recognition of uric acid by AuNPs: an innovative portable tool for the rapid and low-cost identification of clinically relevant biomolecules.

Fatemeh Farshchi, Arezoo Saadati, Mohammad Hasanzadeh, Farzad Seidi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Nanoparticles: Taking a Unique Position in Medicine.Nanomaterials (Basel, Switzerland) · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fatemeh FarshchiJiangsu Co-Innovation Center for Efficient Processing and Utilization of Forest Resources, International Innovation Center for Forest Chemicals and Materials, Nanjing Forestry University Nanjing 210037 China f_seidi@njfu.edu.cn.
Arezoo SaadatiDrug Applied Research Center, Tabriz University of Medical Sciences Tabriz Iran.
Mohammad HasanzadehPharmaceutical Analysis Research Center, Tabriz University of Medical Sciences Tabriz Iran hasanzadehm@tbzmed.ac.ir.ORCID https://orcid.org/0000-0003-4918-1239
Farzad SeidiJiangsu Co-Innovation Center for Efficient Processing and Utilization of Forest Resources, International Innovation Center for Forest Chemicals and Materials, Nanjing Forestry University Nanjing 210037 China f_seidi@njfu.edu.cn.ORCID https://orcid.org/0000-0001-5510-9554

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uric acid (UA) is the end product of purine metabolism. Uric acid is usually excreted in the urine, but its abnormal increase and toxic amount can lead to diseases such as gout, hyperuricemia, Lesch-Nyhan syndrome, and cardiovascular disease. On the other hand, UA reduction can lead to neurodegenerative diseases such as sarcoma, glioblastoma, Hodgkin, and

Identifiers

PMID35480692
PMCPMC9037795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.